Expression of GLUT1 in primary renal tumors: morphologic and biologic implications.
This study aimed to assess whether glucose transporter 1 (GLUT1) is useful in prognostication or differential diagnosis of renal tumors. GLUT1 immunostain for 228 renal tumors showed a membranous or cytoplasmic pattern. The membranous pattern was seen in 86.2% of 145 clear cell renal cell carcinomas (RCCs) and 100% of 11 transitional cell carcinomas (TCCs) but in no oncocytomas, other subtypes of RCC, or sarcomatoid areas of RCCs. The cytoplasmic pattern was seen in 55.2% of 145 clear cell RCCs, 38% of papillary RCCs (11/29), 13% of chromophobe RCCs (2/16), 22% of oncocytomas (5/23), and 82% of TCCs (9/11). Western blot showed a markedly increased GLUT1 protein content in clear cell RCCs compared with a low level in papillary RCCs and normal kidney specimens. GLUT1 expression in clear cell RCC was not significantly correlated with patient survival, tumor grade, or tumor stage. GLUT1 may be a novel target for immunotherapy and a useful marker in the differential diagnosis and classification of renal tumors.
Ozcan
Ayhan
A
Department of Pathology, Methodist Hospital, Houston, TX 77030, USA.
Shen
Steven S
SS
Zhai
Qihui Jim
QJ
Truong
Luan D
LD
D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000473:pathology*; D051272:Glucose Transporter Type 1 / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000473:pathology*; D009367:Neoplasm Staging
D051272:Glucose Transporter Type 1; C495677:SLC2A1 protein, human